{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T20:54:10Z","timestamp":1725656050599},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T00:00:00Z","timestamp":1427673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>There are limited data on retreatment with monoclonal antibodies (<jats:styled-content style=\"fixed-case\">mA<\/jats:styled-content>b) in patients with chronic lymphocytic leukaemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>). In a pivotal study, ofatumumab (human anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 <jats:styled-content style=\"fixed-case\">mA<\/jats:styled-content>b) monotherapy demonstrated a 47% objective response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>) in fludarabine refractory <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> patients. From this study, a subset of 29 patients who had at least stable disease and then progressed were retreated with eight weekly ofatumumab infusions (induction treatment period), followed by monthly infusions for up to 2\u00a0years (maintenance treatment period). The <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> after 8\u00a0weeks of induction retreatment was 45% and 24% had continued disease control after maintenance at 52\u00a0weeks. Efficacy and safety of the retreated patients were compared with their initial results in the pivotal study. Response duration was 24\u00b71\u00a0months vs. 6\u00b78\u00a0months; time to next therapy was 14\u00b78\u00a0months vs. 12\u00b73\u00a0months; and progression\u2010free survival was 7\u00b74\u00a0months vs. 7\u00b79\u00a0months (medians). Upon retreatment, 72% had infusion reactions, mostly Grade 1\u20132. Three patients had fatal infections. In summary, ofatumumab retreatment and maintenance therapy was feasible in patients with heavily pretreated <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> and appeared to result in more durable disease control than initial ofatumumab treatment in this subset of patients who may have a more favourable disease profile.<\/jats:p>","DOI":"10.1111\/bjh.13380","type":"journal-article","created":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T09:20:03Z","timestamp":1427707203000},"page":"40-49","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ofatumumab retreatment and maintenance in fludarabine\u2010refractory chronic lymphocytic leukaemia patients"],"prefix":"10.1111","volume":"170","author":[{"given":"Anders","family":"\u00d6sterborg","sequence":"first","affiliation":[{"name":"Department of Haematology Karolinska University Hospital Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"The University of Texas M.D. Anderson Cancer Center Houston TX USA"},{"name":"Cancer Therapy Research Center San Antonio TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine\/Haemato\u2010Oncology Faculty Hospital Brno Brno Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[{"name":"Johannes\u2010Gutenberg\u2010Universtitaer Mainz Mainz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospital Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[{"name":"Univesitatetsklinickum Carl Gustav Carus Dresden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Schuh","sequence":"additional","affiliation":[{"name":"Churchill Hospital Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luk\u00e1\u0161","family":"Smolej","sequence":"additional","affiliation":[{"name":"Faculty of Medicine in Hradec Kralove University Hospital and Charles University in Prague Hradec Kralove Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Beck","sequence":"additional","affiliation":[{"name":"Haematologisch\u2010Onkologisches Institut Moenchengladbach\u2010Rheydt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Dreyfus","sequence":"additional","affiliation":[{"name":"Hopital Jean Bernanrd Poitiers France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Hellman","sequence":"additional","affiliation":[{"name":"Akademia Medyczna w Gdansku Gdansk Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Kozlowski","sequence":"additional","affiliation":[{"name":"Universitetssjukhuset Orebro Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[{"name":"Universitaesklinikum des Saarlandes Homburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Rizzi","sequence":"additional","affiliation":[{"name":"Azienda Ospendaliero Universitaria Policlinico Consorziale Bari Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Spacek","sequence":"additional","affiliation":[{"name":"Fakultni nemocnice Praha10 Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Phillips","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira V.","family":"Gupta","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Williams","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxanne C.","family":"Jewell","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Nebot","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline Research Triangle Park NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen","family":"Lisby","sequence":"additional","affiliation":[{"name":"Genmab, AS Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J. S.","family":"Dyer","sequence":"additional","affiliation":[{"name":"Ernest and Helen Scott Haematological Research Institute University of Leicester Leicester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,3,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202645"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.827786"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_2_8_10_1","article-title":"Rituximab maintenance after chemoimmunotherapy induction in 1st and 2nd line imporves progression free survival: planned interim analysis of the international randomized AGMT\u2010CLL8\/a Mabtenance trial","volume":"124","author":"Greil R.","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117671"},{"key":"e_1_2_8_12_1","unstructured":"Howlader N. Noone A.M. Krapcho M. Garshell J. Miller D. Altekruse S.F. Kosary C.L. Yu M. Ruhl J. Tatalovich Z. Mariotto A. Lewis D.R. Chen H.S. Feuer E.J.&Cronin K.A.(eds). (2014)SEER Cancer Statistics Review 1975\u20132011.National Cancer Institute Bethesda MD.http:\/\/seer.cancer.gov\/csr\/1975_2011\/ based on November 2013 SEER data submission posted to the SEER web site April 2014."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000006547"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_2_8_15_1","article-title":"A multicenter, phase IV observational study of ofatumumab in chronic lymphocytic leukemia (CLL): a European research initiative on CLL (ERIC) study","volume":"122","author":"Moreno C.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_16_1","first-page":"22","article-title":"Maintenance therapy for B\u2010chronic lymphocytic leukemia","volume":"9","author":"O'Brien S.","year":"2011","journal-title":"Clinical Advances in Hematology & Oncology"},{"key":"e_1_2_8_17_1","article-title":"Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: PROLONG study interim analysis results","author":"Oers M.","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0759-5"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.146"},{"key":"e_1_2_8_20_1","article-title":"Ofatumumab (OFA) vs. physician's choice (PC) of therapy in patients (pts) with bulky fludarabine refractory (BFR) chronic lymphocytic leukemia (CLL): results of the phase III study OMB114242","volume":"122","author":"\u00d6sterborg A.","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.9695"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.07.005"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701573257"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0039"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.516"},{"key":"e_1_2_8_27_1","article-title":"Final analysis from the international trial of single\u2010agent ofatumumab in patients with fludarabine\u2010refractory chronic lymphocytic leukemia","volume":"116","author":"Wierda W.G.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3187"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348656"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13380","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:02:43Z","timestamp":1696327363000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,30]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/bjh.13380"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13380","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,30]]},"assertion":[{"value":"2014-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}